A retrospective trial of abiraterone assessing abiraterone withdrawal syndrome (AWS) in patients with metastatic castration-resistant prostate cancer (mCRPC)

Trial Profile

A retrospective trial of abiraterone assessing abiraterone withdrawal syndrome (AWS) in patients with metastatic castration-resistant prostate cancer (mCRPC)

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Mar 2016

At a glance

  • Drugs Abiraterone acetate (Primary) ; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top